文献速递胸部肿瘤

晚期非小细胞肺癌老年患者接受免疫治疗或化学免疫治疗

Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer.
PubMed 文献 · JAMA Oncol · 2024-01-01

这项在日本58个中心开展的回顾性队列研究纳入1245例75岁及以上晚期非小细胞肺癌患者,比较一线免疫联合化疗与免疫单药等方案的疗效与安全性。倾向性评分匹配后,免疫联合化疗与免疫单药在总生存和无进展生存上无显著差异,但免疫联合化疗组3级及以上免疫相关不良事件发生率更高。

要点

  • 倾向性评分匹配后,免疫联合化疗与免疫单药在总生存和无进展生存上无显著差异。
  • PD-L1表达1%及以上时,免疫联合化疗对比免疫单药的总生存HR为0.98(95%CI 0.67-1.42;P=0.90)。
  • 免疫联合化疗组3级及以上免疫相关不良事件发生率为24.3%,免疫单药组为17.9%(P=0.03)。

核心结论

  • 在75岁及以上晚期非小细胞肺癌患者中,免疫联合化疗与免疫单药相比未改善生存,且增加3级及以上免疫相关不良事件发生率。
  • 基于这些结果,作者认为PD-L1阳性非小细胞肺癌老年患者可考虑免疫单药治疗(may be recommended)。

研究设计与样本

  • 回顾性队列研究,纳入日本58个中心。
  • 队列为75岁及以上、临床IIIB、IIIC、IV期或术后/放疗后复发的非小细胞肺癌患者,于2018年12月至2021年3月期间开始一线全身治疗。
  • 排除接受一线分子靶向药物的患者;数据分析时间为2022年2月至2022年10月。

主要发现

  • 共纳入1245例患者(中位[范围]年龄78[75-95]岁;967例[78%]为男性)。
  • PD-L1表达小于1%者268例(22%);1%至49%者387例(31%);50%及以上者410例(33%);表达未知者180例(14%)。
  • 中位总生存:免疫联合化疗组(354例,28%)为20.0个月(95%CI 17.1-23.6);免疫单药组(425例,34%)为19.8个月(95%CI 16.5-23.8);含铂双药化疗组(311例,25%)为12.8个月(95%CI 10.7-15.6);单药化疗组(155例,12%)为9.5个月(95%CI 7.4-13.4)。
  • 倾向性评分匹配后,免疫联合化疗组与免疫单药组各118例,总生存和无进展生存均无显著差异;PD-L1表达1%及以上时,总生存HR为0.98(95%CI 0.67-1.42;P=0.90),无进展生存HR为0.92(95%CI 0.67-1.25;P=0.59)。
  • 按PD-L1表达1%-49%或≥50%分别分析,同样未达到统计学显著性。

临床怎么用

  • 作者认为,基于这些结果,PD-L1阳性非小细胞肺癌老年患者可考虑免疫单药治疗(may be recommended)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Immune checkpoint inhibitor (ICI) plus chemotherapy combination treatment (ICI-chemotherapy) is now a standard treatment for non-small cell lung cancer (NSCLC) without targetable oncogene alterations, but there are few data on ICI-chemotherapy for patients 75 years and older. OBJECTIVE: To inform the choice of first-line drugs in clinical practice and assess the safety and efficacy of ICI-chemotherapy combination treatment in older adult patients with previously untreated advanced NSCLC. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included 58 centers in Japan. The cohort consisted of patients 75 years and older with clinical stage IIIB, IIIC, IV, postoperative or radiotherapy recurrent NSCLC. Patients started first-line systemic therapy between December 2018 and March 2021. Those receiving first-line molecular targeted drugs were excluded. The data were analyzed from February 2022 to October 2022. EXPOSURES: Systemic therapy. MAIN OUTCOMES AND MEASURES: The main outcomes were overall survival (OS), progression-free survival (PFS), and safety. RESULTS: A total of 1245 patients (median [range] age, 78 [75-95] years; 967 [78%] male) with NSCLC were included in the cohort. Programmed death ligand-1 (PD-L1) expression of less than 1% occurred in 268 tumors (22%); 1% to 49% in 387 tumors (31%); 50% and higher in 410 tumors (33%), and unknown expression in 180 tumors (14%). Median OS was 20.0 (95% CI, 17.1-23.6) months for the 354 patients receiving ICI-chemotherapy (28%); 19.8 (95% CI, 16.5-23.8) months for the 425 patients receiving ICI alone (34%); 12.8 (95% CI, 10.7-15.6) months for the 311 patients receiving platinum-doublet chemotherapy (25%); and 9.5 (95% CI, 7.4-13.4) months for the 155 patients receiving single-agent chemotherapy (12%). After propensity score matching, no differences in OS and PFS were found between the patients receiving ICI-chemotherapy vs ICI alone. Each group consisted of 118 patients. For PD-L1 expression of 1% and higher the OS hazard ratio (HR) was 0.98 (95% CI, 0.67-1.42; P = .90), and the PFS HR was 0.92 (95% CI, 0.67-1.25; P = .59). Significance was also not reached when separately analyzed for lower or higher PD-L1 expression (1%-49% or ≥50%). However, grade 3 or higher immune-related adverse events occurred in 86 patients (24.3%) treated with ICI-chemotherapy and 76 (17.9%) with ICI alone (P = .03). CONCLUSIONS AND RELEVANCE: In this study, ICI-chemotherapy combination treatment did not improve survival and increased the incidence of grade 3 and higher immune-related adverse events compared with ICI alone in patients 75 years and older. Based on these results, ICI alone may be recommended for older adult patients with PD-L1-positive NSCLC.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Tsukita Y, Tozuka T, Kushiro K, et al. Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non-Small Cell Lung Cancer. JAMA Oncol. 2024. PMID: 38451530. doi:10.1001/jamaoncol.2023.6277

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。